“In the next 100 years we want any youth in America to feel very, very welcome to come into our programs,” said Roger Krone, who took over last fall as president and CEO.
While no psychedelic-based therapy has been approved yet in the U.S., Lykos Therapeutics studied MDMA, more commonly called ecstacy or molly, in two late-stage studies.